VP601

VP601 is a small-molecule tubulin-binding agent that was originally developed as part of the VP600 oncology program. Licensed from the University of Medicine and Dentistry of New Jersey (UMDNJ), the compound functions as a potent inhibitor of tubulin polymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. In preclinical studies, VP601 demonstrated broad-spectrum cytotoxic activity against a variety of tumor types, including cervical, ovarian, breast, prostate, leukemia, and colon cancers. It was particularly noted for its efficacy against multi-drug resistant (MDR) tumor cell lines. Structurally, the compound is characterized by its low molecular weight and oral bioavailability. Development was spearheaded by Virium Pharmaceuticals, which was acquired by MacroChem Corporation in 2008, and subsequently by Access Pharmaceuticals in 2009. However, clinical development of the compound appears to have stalled in the early stages.